Science 9 May 2014:
Vol. 344 no. 6184 pp. 588-589
DOI: 10.1126/science.1254990
PERSPECTIVE
AIDS/HIV
Host Controls of HIV Neutralizing Antibodies
Barton F. Haynes, Laurent Verkoczy
+ Author Affiliations
Duke Human Vaccine Institute, Departments of Medicine, Immunology and Pathology, Duke University School of Medicine, Durham, NC 27710, USA.
E-mail: barton.haynes@duke.edu.
A key goal of developing a vaccine for human immunodeficiency virus–1 (HIV-1) is that it should stimulate the production of broadly neutralizing antibodies (bnAbs) that recognize conserved regions of the viral envelope. Unfortunately, no candidate vaccine has proved capable of eliciting such antibodies, possibly because conserved epitopes are obscured by dense glycan “shields” on the viral surface, or because of a failure to produce HIV-1 envelope immunogens that retain their native structure. After 20 years of immunization studies and three HIV-1 vaccine efficacy trials, the induction of bnAb responses by HIV vaccines remains elusive. However, progress in circumventing host factors that limit bnAb induction is now leading to new concepts in vaccinology and immunogen design that hopefully can be applied not only to HIV-1, but also to other vaccines in need of bnAb induction such as for hepatitis C and influenza viral infections.
Read the Full Text
The editors suggest the following Related Resources on Science sites
In Science Translational Medicine
RESEARCH ARTICLE
HIV
Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination
Nicole L. Yates, Hua-Xin Liao, Youyi Fong, Allan deCamp, Nathan A. Vandergrift, William T. Williams, S. Munir Alam, Guido Ferrari, Zhi-yong Yang, Kelly E. Seaton, Phillip W. Berman, Michael D. Alpert, David T. Evans, Robert J. O’Connell, Donald Francis, Faruk Sinangil, Carter Lee, Sorachai Nitayaphan, Supachai Rerks-Ngarm, Jaranit Kaewkungwal, Punnee Pitisuttithum, James Tartaglia, Abraham Pinter, Susan Zolla-Pazner, Peter B. Gilbert, Gary J. Nabel, Nelson L. Michael, Jerome H. Kim, David C. Montefiori, Barton F. Haynes, and Georgia D. Tomaras
Sci Transl Med 19 March 2014: 228ra39.
Abstract Full Text Full Text (PDF) Supplementary Materials
RESEARCH ARTICLE
HIV
Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines
Amy W. Chung, Musie Ghebremichael, Hannah Robinson, Eric Brown, Ickwon Choi, Sophie Lane, Anne-Sophie Dugast, Matthew K. Schoen, Morgane Rolland, Todd J. Suscovich, Alison E. Mahan, Larry Liao, Hendrik Streeck, Charla Andrews, Supachai Rerks-Ngarm, Sorachai Nitayaphan, Mark S. de Souza, Jaranit Kaewkungwal, Punnee Pitisuttithum, Donald Francis, Nelson L. Michael, Jerome H. Kim, Chris Bailey-Kellogg, Margaret E. Ackerman, and Galit Alter
Sci Transl Med 19 March 2014: 228ra38.